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Collaborative European NeuroTrauma
Effectiveness Research in Traumatic Brain Injury
(CENTER-TBI): A Prospective Longitudinal
Observational Study
BACKGROUND: Current classification of traumatic brain injury (TBI) is suboptimal, and
management is based on weak evidence, with little attempt to personalize treatment. A
need exists for new precision medicine and stratified management approaches that
incorporate emerging technologies.
OBJECTIVE: To improve characterization and classification of TBI and to identify best
clinical care, using comparative effectiveness research approaches.
METHODS: This multicenter, longitudinal, prospective, observational study in 22
countries across Europe and Israel will collect detailed data from 5400 consenting pa-
tients, presenting within 24 hours of injury, with a clinical diagnosis of TBI and an
indication for computed tomography. Broader registry-level data collection in approx-
imately 20 000 patients will assess generalizability. Cross sectional comprehensive
outcome assessments, including quality of life and neuropsychological testing, will be
performed at 6 months. Longitudinal assessments will continue up to 24 months post
TBI in patient subsets. Advanced neuroimaging and genomic and biomarker data will be
used to improve characterization, and analyses will include neuroinformatics approaches
to address variations in process and clinical care. Results will be integrated with living
systematic reviews in a process of knowledge transfer. The study initiation was from
October to December 2014, and the recruitment period was for 18 to 24 months.
EXPECTED OUTCOMES: Collaborative European NeuroTrauma Effectiveness Research in
TBI should provide novel multidimensional approaches to TBI characterization and clas-
sification, evidence to support treatment recommendations, and benchmarks for quality
of care. Data and sample repositories will ensure opportunities for legacy research.
DISCUSSION: Comparative effectiveness research provides an alternative to reduc-
tionistic clinical trials in restricted patient populations by exploiting differences in
biology, care, and outcome to support optimal personalized patient management.
KEY WORDS: Clinical study, Comparative effectiveness research, Protocol, Traumatic brain injury
Neurosurgery 76:67–80, 2015 DOI: 10.1227/NEU.0000000000000575 www.neurosurgery-online.com
GENERAL INFORMATION
Short Study Title
CENTER-TBI Study
Protocol
Version 4.2
Version Date
28 August 2014
Andrew I.R. Maas, MD, PhD*
David K. Menon, MD, PhD‡
Ewout W. Steyerberg, PhD§
Giuseppe Citerio, MD¶
Fiona Lecky, MD, PhDk
Geoffrey T. Manley, MD, PhD#
Sean Hill, PhD**
Valerie Legrand, PharmD‡‡
Annina Sorgner, MEc§§
on behalf of the CENTER-TBI
Participants and Investigators
(see Appendix)
*Department of Neurosurgery, Antwerp Univer-
sity Hospital andUniversity of Antwerp, Edegem,
Belgium; ‡Division of Anaesthesia, University of
Cambridge/Addenbrooke’s Hospital, Cambridge,
UK; §Department of Public Health, Center
for Medical Decision Making, Erasmus MC—
UniversityMedical Center Rotterdam, Rotterdam,
The Netherlands; ¶Department of Health
Science, University of Milan-Bicocca; Neuro-
Intensive Care, Department of Emergency and
Intensive Care, San Gerardo Hospital, Monza,
Italy; kEmergencyMedicine Research in Sheffield,
Health Services Research Section, School of
Health andRelatedResearch (ScHARR), University
of Sheffield, Sheffield, UK; #Department of
Neurological Surgery, University of California,
San Francisco, California; **International Neuro-
informatics Coordinating Facility, Karolinska
Institutet, Stockholm, Sweden; ‡‡ICON plc, VP
Global project management, Dublin, Ireland;
§§GABO:mi, International projects manage-
ment, Munich, Germany
Correspondence:
Andrew I.R. Maas, MD, PhD,
Department of Neurosurgery,
Antwerp University Hospital/University
of Antwerp,
Wilrijkstraat 10,
2650 Edegem Belgium.
E-mail: andrew.maas@uza.be
Received, August 29, 2014.
Accepted, September 2, 2014.
Published Online, September 24, 2014.
Copyright © 2014 by the
Congress of Neurological Surgeons.
WHAT IS THIS BOX?
A QR Code is a matrix
barcode readable by QR
scanners, mobile phones
w i t h came r a s , a nd
smartphones. The QR
Code above links to
Supplemental Digital
Content from this article.
This is an open-access article distributed under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivatives 3.0
License, where it is permissible to download and share the work
provided it is properly cited. The work cannot be changed in any way
or used commercially.
Supplemental digital content is available for this article.
Direct URL citations appear in the printed text and are
provided in the HTML and PDF versions of this article on
the journal’s Web site (www.neurosurgery‐online.com).
RESEARCH—HUMAN—STUDY PROTOCOLS
NEUROSURGERY VOLUME 76 | NUMBER 1 | JANUARY 2015 | 67
Copyright © Congress of Neurological Surgeons. Unauthorized reproduction of this article is prohibited.
Coordinators
Andrew I.R. Maas, Antwerp University Hospital; David K.
Menon, University of Cambridge
Support
The European Union FP 7th Framework program (grant
602150)
Funding of additional elements has been provided by the
Hannelore Kohl Foundation (Germany) and by the non-profit
organization One Mind For Research (directly to INCF).
Contract Research Organization
ICON plc, South County Business Park, Dublin 18, Ireland
Central Laboratory
University of Pecs, 48-as tér 1, Pecs 7622, Hungary
Data Entry Tool Developed by
QuesGen, 800 Airport Blvd 410, Burlingame, CA94010, USA
Database and Data Analysis Platform
Coordinated by the International Neuroinformatics Coordi-
nating Facility (INCF, Karolinska Institutet, Nobels väg 15A,
17177 Stockholm, Sweden) with additional support from One
Mind for Research
Neuroimaging Repository
icoMetrix, Tervuursesteenweg 244, 3001 Leuven, Belgium
Study Registration
Clinicaltrials.gov: NCT02210221
T
he Collaborative European NeuroTrauma Effectiveness
Research in Traumatic Brain Injury (CENTER-TBI) core
data study and CENTER-TBI registry (NCT02210221)
form part of the CENTER-TBI project: a large-scale project
supported by the European Union Framework 7 program (grant
602150). It is embedded within the framework of the Interna-
tional Initiative on TBI Research (InTBIR).1
Each year, approximately 2.5 million people will experience some
formof traumatic brain injury (TBI) in Europe; of these, 1millionwill
be admitted to the hospital and 75 000 will die. TBI thus constitutes
a major cause of death and disability, leading to great personal
suffering for victims and relatives and huge direct and indirect costs to
society. In the United States, the annual burden of TBI has been
estimated at .$75 billion in patients with TBI.2 The lifetime costs-
per-case is estimated at $396 000, with disability and lost productivity
costs outweighing medical and rehabilitation costs by a factor of 4.3
TBI is considered the most complex disease in our most complex
organ. It is characterized by great heterogeneity in terms of etiology,
mechanisms, pathology, severity, and treatment, with widely varying
outcomes. Falls and high velocity road traffic incidents cause different
types of injury. TBI may consist of diffuse damage, contusional brain
damage, or intracranial hematomas. Some structural abnormalities
(particularly traumatic axonal injury) are poorly detected by conven-
tional imaging. The clinical severity of TBI ranges from minor
(minimal complaints, no visible structural damage) to virtually
unsurvivable injuries. We have found large differences in outcome
between centers with up to a 6-fold higher risk in poorer vs better
centers after adjustment for chance effects and casemix.4 We now also
recognize that TBI is not just an acute event, but can trigger a chronic
process, with progressive injury over hours, days, weeks, months, and
even years.5 The long-term sequelae related to behavior, emotion, and
cognition, including early-onset dementia and psychiatric illness as
well as later substance-use disorders particularly after repetitive mild
TBIs, constitute an increasing societal and economic burden.6-8
While basic research has increased our knowledge of the mechanisms
involved, improvements in clinical management have not kept pace.
Guidelines for the treatment of TBI are available,9,10 but the evidence
underpinning these recommendations is weak. Moreover, current
approaches to the characterization of disease severity and outcome are
unidimensional and have not undergone refinement for.3 decades.
Treatment generally follows a one-size-fits-all approach and is not
targeted to the needs of an individual. Clinical research in TBI is
particularly challenging due to disease heterogeneity and has been
further hampered by dispersion of efforts with little collaboration
between researchers in acute and postacute settings, and by research
that focuses on isolated disease mechanisms, testing highly specific
neuroprotective agents in underpowered randomized clinical trials
(RCTs). RCTs generally use strict enrollment criteria in order to
study the investigational intervention in the cleanest setting. The
downside of this approach is that results are only valid in such selected
subpopulations and that generalizability to the real-world context is
limited. Indeed, improvements in TBI care have come not from
clinical trials, but rather from observational studies, guideline
development, and meta-analysis of individual patient data.11
However, the large-scale international observational studies on TBI
in Europe and the United States that underpin these improvements
date back at least 20 years12 and do not reflect current clinical care.
Recent advances in genomics, advanced neuro-imaging, and
biomarker development provide unparalleled opportunities for
refinements in clinical characterization, offering more accurate
disease phenotyping. Improved disease characterization will aid
precision medicine, a concept recently enunciated by the US
National Academy of Sciences.13 Such improved characterization
and stratification will allow for more targeted therapies.
Furthermore, comparative effectiveness research (CER) provides
a promising framework to identify best practices and improve
outcome after TBI. CER is the generation and synthesis of
evidence that compares the benefits and harms of alternative
methods to prevent, diagnose, treat, and monitor a clinical
condition or to improve the delivery of care. The purpose of CER
is to assist consumers, clinicians, purchasers, and policymakers to
make informed decisions that will improve healthcare at both the
individual and population levels.14
A basic concept of CER is to study differences in care and
outcome in observational studies, thus turning natural variability
MAAS ET AL
68 | VOLUME 76 | NUMBER 1 | JANUARY 2015 www.neurosurgery-online.com
Copyright © Congress of Neurological Surgeons. Unauthorized reproduction of this article is prohibited.
into an asset. In CENTER-TBI, we will exploit the existing
heterogeneity in structure, process, and outcome to compare treat-
ments and interventions that are standardpractice in some centers and
countries but not in others. The aim is to discover underlying
pathophysiology, to refine characterization, and to identify effective
clinical interventions. Natural links exist between CER and individ-
ualized approaches, because CER aims to identify the best treatment
for the individual patient, with a specific type of injury, severity,
comorbidities, and other aspects that determine optimal treatment.
We see a great potential for CER in TBI because of various unique
features. First, there are large between-center and between-country
differences in both outcome and management. Second, robust risk
adjustment models have been developed specifically for TBI,
providing the possibility to adjust for patient characteristics that
affect outcome.Third, advanced statisticalmodels, including random
effect models, are available to analyze differences between centers.15
The key driver of our research plan is to collect data from a large
number of European centers and a sufficiently large cohort to
enable CER analyses of differences in clinical care and manage-
ment pathways in TBI. The CENTER-TBI population will be
a unique and well-characterized resource, accessible for longer-
term follow-up with continued funding. The integrated results of
the project will be brought together in a process of translational
outputs. We aim for real-world approaches to translating research
outputs into practical information for patients, healthcare pro-
fessionals, and policymakers. We will develop and sustain an
international TBI knowledge community that integrates results of
the project with high-quality living evidence reviews of the current
state of knowledge, aiming to continuously provide evidence to
underpin guidelines and treatment recommendations. The impact
of CENTER-TBIwill be enhanced by international collaborations
within and beyond InTBIR. TBI is a global problem and requires
a global approach. The CENTER-TBI database and repositories
will be an invaluable resource for further research, which we wish
to encourage. In this article, we present an abbreviated version of
the CENTER-TBI protocol. The full version of the protocol is
available as supplemental material (see Supplemental Digital
Content, http://links.lww.com/NEU/A688).
STUDY GOALS AND OBJECTIVES
The study goals are
• To improve characterization and classification of TBI in
Europe, with inclusion of emerging technologies.
• To identify the most effective clinical care and to provide high-
quality evidence in support of treatment recommendations and
guidelines.
The specific aims are
• To collect high-quality clinical and epidemiological data with
repositories for neuro-imaging, DNA, and serum from patients
with TBI.
• To refine and improve outcome assessment and develop health
utility indices for TBI.
• To develop multidimensional approaches to characterization
and prediction of TBI.
• To define patient profiles that predict efficacy of specific
interventions (precision medicine).
• To develop performance indicators for quality assurance and
quality improvement in TBI care.
• To validate the common data elements (CDEs) for broader use
in international settings.
FIGURE 1. Distribution and number of sites per country that will participate
in the Collaborative European NeuroTrauma Effectiveness Research in
Traumatic Brain Injury.
TABLE 1. Inclusion and Exclusion Criteria of CENTER-TBIa
Inclusion Criteria Exclusion Criteria
CENTER-TBI core study
Clinical diagnosis of TBI Severe preexisting neurological
disorder that would confound
outcome assessments
Clinical indication for CT scan
Presentation within 24 hours
of injury
Informed consent obtained
according to local and
national requirements
CENTER-TBI registry
Clinical diagnosis of TBI None
Clinical indication for CT scan
aCENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in
Traumatic Brain Injury; CT, computed tomographic; TBI, traumatic brain injury.
CENTER-TBI: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY
NEUROSURGERY VOLUME 76 | NUMBER 1 | JANUARY 2015 | 69
Copyright © Congress of Neurological Surgeons. Unauthorized reproduction of this article is prohibited.
• To develop an open database compatible with the Federal
Interagency Traumatic Brain Injury Research (FITBIR).
• To intensify networking activities and international collabo-
rations in TBI.
• To disseminate study results and management recommenda-
tions for TBI to healthcare professionals, policymakers, and
consumers, aiming to improve healthcare for TBI at individual
and population levels.
• To develop a knowledge commons for TBI, integrating
CENTER-TBI outputs into systematic reviews.
STUDY DESIGN
Overall Design and Project Management
CENTER-TBI is a prospective longitudinal nonrandomized
observational study across the severity spectrum of TBI in up to
80 sites from 22 countries for 18 months. A detailed overview of
the distribution of sites is provided in Figure 1. With a large
number of centers participating, it is to be expected that some
changes may occur during the course of the project. Updated
information will be provided on the CENTER-TBI website:
www.center-tbi.eu. We will characterize centers with regard to
their structural profile in order to explore effects of organi-
zational aspects. The study will consist of 2 parts: CENTER-
TBI core data study (n = 5400) and CENTER-TBI registry
(n = 15 000-25 000). Inclusion and exclusion criteria are
summarized in Table 1. The CENTER-TBI registry will be
based on pragmatic data collection of all patients with TBI
seen in participating centers, aiming to establish the internal
generalizability of our study, and to establish the external
generalizability by comparison with national trauma registries.
In the core data study, we will create and maintain well-curated
biorepositories for analysis by the participants and to provide
for legacy research with future new methodologies or longer
follow-up of outcome (supported by future grant funding).
The CENTER-TBI study will be overseen by the Coordinators
of the CENTER-TBI project, Prof Andrew I.R. Maas (University
Hospital Antwerp) and Prof David Menon (University of
Cambridge), supported by the project management committee.16
National coordinators have been designated to streamline study
efforts in each country. The logistics and quality of the data
collection will be overseen by ICON, Plc, a professional contract
research organization. Source data verification will be performed
in 10% of the subjects. The data entry and analysis platform are
developed by Quesgen Inc17 in collaboration with Karolinska
Institutet International Neuroinformatics Coordinating Facility
(KI-INCF18), with additional support from One Mind for
Research (http://www.onemind.org/).19
CENTER-TBI Core Data Study
In the CENTER-TBI Core data study, we will follow the
disease course with detailed data collection up to 2 years postinjury
for the most severely injured patients, thus bridging the acute and
postacute phases. Patients will be stratified upon enrollment into 3
clinical groups differentiated by clinical care path:
Emergency room (ER) stratum: patients evaluated in the ER
and discharged (n = 1800).
Admission stratum: patients admitted to the hospital but not to
the intensive care unit (ICU; n = 1800).
ICU stratum: patients admitted directly from ER or other
hospital to the ICU (n = 1800).
We aim for an equal balance in numbers between the strata:
approximately 1800 patients per stratum.
CENTER-TBI Registry
The CENTER-TBI registry will serve 2 important purposes: 1)
assessing representativeness of the CENTER-TBI core study and
2) providing opportunities for comparative effectiveness analysis of
organization of care. Elementary data from all patients excluded
from the core data collection for whatever reason, but who do have
a clinical diagnosis of TBI and undergo CT scanning, will be
recorded in the registry.
Time Frames
The setup phase of the project (currently underway) will last
approximately 1 year. Recruitment will be initiated across the
participating study centers between November 2014 and January
2015. Recruitment is expected to last about 18 months, but may
be extended in case of slower recruitment. The index follow-up for
outcome assessment will be at 6 months. Allowing for data
verification and cleanup, we expect definitive analyses on the
complete database to start in 2017.
Sample Size Calculation and Statistical Analyses
The sample size estimate is based on:
• Practical logistic considerations.
• Power calculations for the different strata, targeting compar-
ative effectiveness analyses, assuming a between-center
and between-country heterogeneity as identified in previous
research (expressed by variance parameter from a random
effects model, t2 of 0.431).
• Postulated odds ratios for intervention effects of approximately
5% improvement in outcome.
Overall, these calculations provide a statistical power to detect
odds ratios of 1.2 associated with differences in process
characteristics of specific interventions across the core dataset
with a power of 80%. Somewhat larger odds ratios are required
for interventions applicable in only 1 of the 3 individual strata in
the core dataset. In the registry we expect to be able to detect
differences (predominantly in organizational or system character-
istics) with an odds ratio of 1.2 with a power of 82%.
Statistical analyses for the CER questions will primarily apply
random effects modeling, in which the center is included at the
higher level, and patients are considered clustered within centers.
In some analyses, higher levels of clustering will also be considered
(eg, country or European region) or lower levels (eg, physicians)
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within hospitals. Confounding factors as measured at the
individual patient or center level will be considered extensively
and will be targeted to the specific research question.
The analyses for better characterization of TBI will be
exploratory, aiming to better understand the complexity of the
disease and to discover new associations. In addition to standard
statistical descriptive and inferential techniques, we will also use
novel machine learning techniques as appropriate.
Prognostic analyses will consider a range of variables, including
genetic, demographic, and clinical data, physiological signals,
imaging results, and biomarkers as predictors of early endpoints
and physiologic derangement (eg, raised intracranial pressure), and
late outcome, including mortality, functional outcome, quality of
life, and neuropsychological performance. Previously and newly
developed prediction models will be validated by comparison of
observed to predicted outcome risks, with predictive performance
summarized by measures for discrimination and calibration.
Data Management
Prior to upload to the study database, acquired data will be stored
locally. All patients will be allocated a random Global Unique
Personal Identificationnumber (GUPI), whichwill be linked locally
to hospital identifiers. Uploaded data will be de-identified and
images will be defaced prior to upload. While blood samples and
clinical data will be linked, both sets of data will be kept confidential
and anonymized beyond the initial stage of correlation for analysis.
Imaging and electronic data will be kept on individually password-
protected servers. Clinical data will be entered into electronic Case
Report Forms (eCRFs) and managed by the QuesGen data
management platform,17 which will be developed in collaboration
with KI-INCF.18 Data collection is based upon the CDEs,20 thus
providing evidence context for further refinement and updating of
the CDEs in an international setting, which will inform global
standardization of data collection in TBI. The database structure
will be compatible with FITBIR.21 As data are entered into each
form, the system will run data validation checks that include
conditionally required data, validation across fields, and validation
requirements based on subject type. If any validation check fails,
the user is alerted immediately that the data do not meet quality
assurance (QA) criteria and the issue can be addressed and
corrected at that point. All de-identified electronic study data in the
CENTER-TBI database will be stored securely in the European
data space under supervision of KI-INCF for the duration of
subject enrollment and follow-up and for a period afterwards for
data analysis and preparation of publications. We estimate that the
analysis and publication period will last for several years after the
conclusion of subject enrollment.
Together with QuesGen Systems, KI-INCF will ensure that
data standards are established for the datamodel (eg, conformity of
field formats, field codes, and names to ensure consistency across
all datasets). Any approved changes will be fully documented with
dataset updates to maintain data quality and accuracy. KI-INCF
will be responsible for importing cleaned datasets to other analytic
platforms as determined by the coordinators. ICON will under-
take source data verification in 10% of datasets, using an approach
for dataset selection, which depends (among other factors) on
recruitment rates and assessment of data completion and accuracy
on the online data entry forms.
Where applicable, derived information relevant to the patient’s
care will be made available to the physician responsible. Data,
including blood samples collected as part of this study, will be
shared in an anonymized form with collaborators from other
European states (this is part of a European Union Framework7
funded program), and with selected collaborators in other
countries who form part of the International Traumatic Brain
Injury Research Initiative.
TheKI-INCFwill coordinate the establishment of an informatics
platform for acquisition, storage, and analysis of CDE-based clinical
data. The goal is to develop a next-generation open standards-based
platform to support advanced large-scale analytics and model
building. Such a platform also provides a model for future clinical
studies on brain diseases and disorders. This development will
receive additional support from One Mind for Research.19
Data sharing policies, providing open access, modelled on the
Alzheimer’s Disease Neuroimaging Initiative (ADNI22) concept,
will aim to broaden access to the data, encourage academic
productivity, and accelerate outputs. CENTER-TBI participants
and investigators will have equal access rights to the data.
Ethical Considerations
Informed consent procedures will follow local and national
requirements in all cases. We anticipate that many potential
patients will not be able to consent to their participation in this
project. The nature of TBI means that some patients may lack the
capacity to decide to participate in this study especially at the
earliest time point. It is important to try and include these patients
to ensure that representative samples of patients are included to
avoid bias in the study findings. Every step will be taken to ensure
that a test of capacity is undertaken before a decision on a person’s
capacity to consent or not to consent to participate in research is
taken. If the subject is not capable of self-consent, all efforts
will be made to locate a legally acceptable representative to act
on behalf of the subject. When a legally acceptable representative
(eg, consultee/proxy) is identified, an opinion will be sought
about the potential participant’s wishes and feelings in relation to
the project, and whether he or she would have wanted to take part
in the study.
Subjects are free to withdraw, or be withdrawn by their
consultee/proxy if appropriate, at any point in the study, and
they need not state a reason. All individual patient identifiers will
be stripped from data before storage on the study database (see
details under Data Management). The study will adhere to
national and European regulatory requirements. We recognize
that these may vary between European Union member states, and
one of the aims of CENTER-TBI is to map this variance in the
course of the study.
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Subject Risks and Benefits
No structured adverse event reporting will be implemented, as
this is an observational study without any therapeutic interven-
tion. However, we will capture any serious complication that may
occur during the clinical course in the CRF. Diagnostic inter-
ventions include blood sampling, outcome assessments, and, in
selected sites, magnetic resonance (MR) imaging, high-resolution
ICU monitoring, and extended blood sampling. The potential
risks to the subject are minimal across all domains of data
collection.
No direct benefit to study participants is expected, other than by
enhanced contacts and more detailed study assessments. The
results will be directly relevant to society in general and to future
patients who have TBI.
METHODOLOGY
CENTER-TBI Registry
Data collection will be elementary and based on retrospective
extraction from clinical records of data that are routinely collected
clinically. No specific study interventions will be performed.
No target recruitment number has been set for the CENTER-
TBI registry. We anticipate inclusion of approximately 15 000 to
25 000 subjects.
CENTER-TBI Core Study
A total of 5400 patients will be recruited and differentiated
into 3 equal strata of approximately 1800: ER, admission, and
ICU strata, as described above. Balance in numbers between the
strata will be aimed for, but sites will be allowed to arrange
recruitment strategies to best suit their local requirements. We
would anticipate a far larger number of eventual subjects in the
ER and admission strata than in the ICU stratum. Options for
achieving balance would be to limit the recruitment in the ER
and admission strata to certain days per week or certain periods of
time. It would be essential to maintain balance of recruitment
across the days of the week.
A maximum cap of enrollment will be implemented per center
in order to prevent overrepresentation. The cap is currently fixed at
a maximum of 100 patients per stratum with a total number per
center of no more than 250. The following broad categories of
clinical data will be prospectively collected from all enrolled
patients through medical records and personal interview:
• Baseline demographics: age, sex, race, ethnicity, and handedness.
• Baseline socioeconomics: education, employment, living situ-
ation, and types of support.
• Baseline medical history by system including substance abuse,
prior TBI, and medications.
• Mechanism of injury, location, and surrounding circumstances.
• Prehospital clinical course variables: vital signs, transport times,
and Glasgow Coma Scale score.
• Abbreviated injury scale (AIS) score and injury severity score
(ISS).
• Brain computed tomographic (CT) report including presence
of skull fracture and intracranial abnormalities.
• Emergency department clinical course: vital signs, GCS, fluids,
labs, toxicology, and complications.
• Hospital admission clinical course: daily vital signs, GCS,
fluids, labs, complications, and medications.
• Hospital surgeries and neuromonitoring.
• Reasons for clinical decisions.
• Physician-based satisfaction with care and prognostic estimates.
• Admission and discharge dates and times throughout full
clinical course.
• Discharge destination and acute care outcome evaluation.
Source data can include patient medical records (paper and
electronic), ambulance records, online test results, and information
TABLE 2. Timing of Follow-up Assessmentsa
Time Point 2-3 weeks 3 m 6 m 12 m 24 m
ER stratum (1800)
Outcome
Neuropsych 600b 600b 1150
Questionnaires 1400 1300 1250
Admission stratum (1800)
Outcome
Neuropsych 1200 300b only 250b
Questionnaires 1450 1300 1200 (non MR) 250
ICU stratum (1800)
Outcome
Neuropsych 1200 300b only 250b
Questionnaires 1450 1300 1200 250
aER, emergency room; ICU, intensive care unit; MR, magnetic resonance.
bOnly in patients undergoing magnetic resonance studies.
Numbers at follow up are estimated to be lower than the size of the original cohort to allow for mortality and for anticipated loss of follow up.
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held on clinical systems. The Web-based data entry system will use
secure, encrypted connections for data upload. Coding of records by
the GUPI will ensure that names and other identifying information
will not be linked to study data, in compliance with existing
regulations. No data with personal identifiers will leave the study site.
Blood Sampling
Blood samples will be drawn in all patients upon presentation for
routine laboratory testing as dictated by standard clinical procedures.
Details of assays will be captured in the CRF. For study purposes,
adult patients fromall stratawill also have 19mLof blooddrawn,24
hours of injury for biomarker and genetic analysis. While local
research protocols may require the banking of additional volumes of
blood, this should not exceed 40 mL at admission. The blood
sample will be drawn from an arterial or (central) venous catheter
placed as a part of standard care where possible. In other cases,
patients will need to undergo a separate venepuncture. No more
than 2 venepunctures will take place. Whenever possible, blood
draws will be combined with those of routine clinical care.
The additional blood draws performed for purposes of the study
will not exceed 40 mL upon presentation, 75 mL during the acute
clinical course (only ICUstratum), andnomore than 30mLannually
during a 2-year follow-up period. In pediatric patients, blood draws
will be limited to a maximum of 3% of the circulating volume.
In the ICU stratum, more extended sampling will be
performed in a subset of patients. Cross sectional sampling at
follow-up will be performed at 6 months in the admission and
ICU strata and at other time points in those subjects undergoing
MR investigations (Table 2). Sampling kits will be provided to
the sites. These will be in separate biohazard bags for the
biomarker, genetic, and advanced hemostasis samples. All
sample tubes will be color-coded. The sample tube colors will
be finalized once current tendering processes are completed, and
details will be specified in site study manuals. Sampling kits will
be provided to centers by the University of Pecs, which will lead
the biomarker work package.
Processing of Samples for Protein Biomarker Sampling
Time points for protein biomarker sampling are specified in
Table 3. For each sample, 9 mL of blood will be collected into
a serum separator tube, centrifuged after 45 6 15 minutes of
coagulation at room temperature, at 4000 rpm for 10 minutes,
and aliquoted as 8 · 0.5 mL serum into the barcoded 1.2 mL
cryovials. Aliquots should be deep-frozen at 280C within 3
hours. If deep freezing is not directly possible for logistic reasons,
samples may be stored at 220C non-frost-free freezer for
a maximum of 48 hours before being transferred to 280C.
Samples will be transferred to the central laboratory at the
University of Pecs at regular intervals.
Sampling for Genetic Analysis
For genetic studies, two 4.9 mL samples of whole blood will be
collected in potassium EDTA tubes at enrollment and stored at
280C within 6 hours. The 2 samples will be stored in 2 different
racks. One sample will be retained at the site, while the other will
be shipped, in batches, to the central facility in the University of
Pecs along with biomarker and other blood samples. We have
opted for such duplicate sampling in order to have a reserve sample
available in case any sample gets lost during transport or that DNA
extraction process may not be optimal. Collated blood samples
from multiple centers will be batch transferred from Pecs to the
Clinical Genetics Laboratory at Addenbrooke’s Hospital in
Cambridge, which will act as the repository for DNA samples,
extract DNA, and provide aliquots for analysis.
Neuro-Imaging
All acute head CTs and at least 1 follow-up CT scan (if
performed between day 2 and 7 for clinical care) will be collected
and uploaded into the CENTER-TBI neuro-imaging repository.
CT scans performed as part of clinical care will follow standard
clinical practice of the hospital. This will generally include
a follow-up scan in all patients treated surgically performed within
24 hours of surgery. We recommend 3-dimensional volumetric
CTs with a multi-detector row scanner (32 rows or better).
TABLE 3. Planned Sampling Points for Biomarkersa
Time Point Admission/Presentation Day 1 Day 3 Day 4 Day 5 2-3 weeks 3 m 6 m 12 m 24 m
ER stratum (1800)
Biomarkers 1800 (9) 600 (9) 200 (9)
Genetics 1800 (10)
Admission stratum (1800)
Biomarkers 1800 (9) 1200 (9) 300 (9) 250 (9)
Genetics 1800 (10)
ICU stratum (1800)
Biomarkers 1800 (9) 1000 (9) 250 (9) 250 (9) 250 (9) 600 (9) 1200 (9) 300 (9) 250 (9)
Genetics 1800 (10)
aER, emergency room; ICU, intensive care unit.
Figures in columns represent the number of subjects expected to provide samples at each time point, allowing for mortality and loss to follow up. Figures in parentheses
represent provisional amount of the drawn blood in milliliters.
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During upload, the images will be de-identified and defaced and
will only be coded by the assigned GUPI code. All images will be
read and coded by central reviewers at Icometrix in accordance
with the neuro-imaging TBI CDE’s. No additional CT scans will
be performed for study purposes.
Outcomes
All outcome measures will be obtained from the patient if they
are cognitively able, supplemented as appropriate by information
from a caregiver or other proxy. Assessments will be administered
by telephone/postal questionnaire/Web-based questionnaire and
face-to-face visits. In order to maximize the number of subjects in
whom outcome data are obtained, face-to-face visits may be
conducted within the local study site, in the patient’s home, or
other residential/healthcare setting, as appropriate. Where sub-
jects are resident within a long-term rehabilitation care facility,
some assessments and neuropsychological evaluations (such as the
JFK coma recovery scale—revised23) may be available from the
clinical record. A detailed overview of times of outcome
assessments is provided in Table 2.
A prespecified neuropsychological evaluation will be performed
in all strata at 6 months after injury and longitudinally at various
time points in the 3 strata up to 24 months after injury. These
additional assessments will focus on earlier outcome assessments in
ER stratum and later assessments in Admission and ICU strata.
Twomain types of patient follow-up are planned depending on
whether only questionnaires are being used or whether a more
complete neuropsychological assessment is being conducted
(Table 4). The neuropsychological assessment involves face-to-
face contact. Travel expenses of patients will be reimbursed
according to local site policy. Assessment that only involves
questionnaires/interviews will be conducted by a mixture of
telephone follow-up and postal/Web-based questionnaires.
If more convenient, these questionnaire assessments may be
completed as part of a visit.
Outcome assessment will include functional outcome (as assessed
by the Glasgow Outcome Scale extended), heath-related quality of
life, and patient questionnaires. The preferred method of assessing
the Glasgow Outcome Scale extended is by interview, but postal/
Web-based questionnaires will also be options. The face-to-face visits
will include formal neuropsychological testing, including paper and
pencil tests, and the Cantab neuropsychological assessment tests
neuropsychological test battery,24 which is language independent
and therefore admirably suited for a multinational study. Hardware
and software for the Cantab neuropsychological assessment tests
assessments will be provided by the project organization to sites free
of charge. A detailed overview of the instruments used in the various
assessments is summarized in Table 4. Where applicable, license
fees will be covered by the coordinator.
Formal neuropsychological testing will only be performed in
patients considered testable. Assessment of testability will be based
upon the GalvestonOrientation and Amnesia Test.25 Patients with
a score #65 will be considered untestable, and in these patients
assessment will only consist of the JFK coma recovery scale.
Tests will be administered by trained study personnel. In case
any clinically relevant problems are detected during outcome
assessments, the research personnel will notify the medical staff
according to local clinical policies and procedures. Any concerns
related to a study participant will be discussed with the principal
investigator or other senior clinical members of the research team
to ensure appropriate arrangements for patient treatment or
follow-up are in place. In nonurgent cases a letter may be sent to
the patient’s general practitioner outlining these concerns, which
will also be copied to the relevant hospital department.
Extended Studies
Sites have been given the opportunity to contribute to more
extended data collection in the following domains:
• MR imaging
• Extended coagulation and biomarker studies
• High-resolution ICU monitoring
TABLE 4. Outcome Assessment—Instruments and Approximate
Time Requirementsa
Questionnaire follow-upb
Telephone interview or postal questionnaire/
Web-based completion/personal interview
Time: 30 min
Participant questionnaire part A 10
GOSE 10
SF12v2 5
QOLIBRI-OS 5
Postal questionnaire/Web-based completion/
personal interview
Time: 50 min
QOLIBRI 12
Posttraumatic stress disorder (PCL-5) 5
Rivermead post concussion questionnaire 5
SF36v2 12
HADS 5
PHQ-9 5
Neuropsychology follow-upb
Neuropsychology face-to-face visit Time: 102 min
GOAT 5
Testable patients
RAVLT 15
TMT 7
CANTAB 60
10 m walk and timed up and go 5
Untestable patients (if GOAT #65)
JFK Coma Recovery Scale—Revised
aCANTAB, Cantab neuropsychological assessment tests; GOAT, Galveston
Orientation and Amnesia Test; GOSE, Glasgow Outcome Scale Extended; HADS,
Hospital Anxiety and Depression Scale; PCL-5, PTSD Check List; PHQ-9, Patient
Health Questionnaire; QOLIBRI, Quality of Life after Brain Injury; QOLIBRI-OS,
QOLIBRI-Overall Scale; RAVLT, Rey Auditory Verbal Learning Test; SF12v2, Short-
Form 12 version 2; SF36v2, Short-Form 36 version 2; TMT, Trail Making Test.
bFor times, see Table 3.
Final selection of instruments will depend on logistic considerations and obtaining
applicable license agreements at reasonable conditions.
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• Electrocorticographic monitoring
• Continuous electroencephalography monitoring
The selection of sites for such advanced data collection is
determined by expression of interest and logistic considerations. In
addition to data collected specifically as part of CENTER-TBI, we
will also record additional data that are available at individual centers.
None of these data will be mandated as part of CENTER-TBI,
acquisitionwill depend on local clinical judgment, andwill only be
collected if part of routine clinical management or another
ethically approved study with appropriate consent. Such data
could include (but are not limited to) electrocorticography,
continuous electroencephalography, cerebral microdialysis, brain
oxygen monitoring, and other imaging studies. These data will be
used in combined analyses to address the goals of precision
medicine and comparative effectiveness research.
DISCUSSION
CENTER-TBI is a project embedded within the InTBIR,1
which was founded in 2011 as a collaboration between the
European Commission, the US National Institute of Neuro-
logical Disorders and Stroke, and the Canadian Institute of
Health Research and its national funding partners.26 This
collaboration of international funding agencies is unique.
However, perhaps even more unique is the fact that all the
projects will undertake data collection to common standards
based on the Common Data Elements scheme developed by the
National Institute of Neurological Disorders and Stroke,20 with
the database structure that is compatible with FITBIR.21
InTBIR was founded in recognition of the importance of TBI
as a global pandemic, culminating in significant costs to all
societies in terms of mortality, residual disability, health,
economic costs, and reduced activity. Although initiated by 3
funding agencies, InTBIR is an open community and welcomes
participation of other agencies and funding bodies. With the aim
of advancing the care for TBI, the primary intent of InTBIR is to
focus on collecting, standardizing, and sharing clinical TBI data
for comparative effectiveness research. Within the InTBIR
framework, there are currently 10 studies supported by the
participating agencies (Table 5).
CENTER-TBI has interactions with several other studies
within the InTBIR community and has particularly close
collaboration with TRACK-TBI (Transforming Research And
Clinical Knowledge in Traumatic Brain Injury; PI, Dr Geoffrey
Manley), with extensive harmonization of study procedures and
data collection. Pediatric recruitment to CENTER-TBI involves
a close collaboration with ADAPT (Approaches and Decisions for
Acute Pediatric TBI; PI, Dr Michael Bell). The concept of
CENTER-TBI and TRACK-TBI has already attracted substantial
international interest, and satellite projects are currently being set
up inAustralia, China, and India. Thus, the philosophy that TBI is
a global problem that requires a global approach is now being
translated into research practice. The InTBIR studies and satellite
projects linked to these initiatives have the potential to provide
long-needed evidence to support practice recommendations and to
improve treatment.
Details on the CENTER-TBI project and scientific work plan
are available on the CENTER-TBI website: www.center-tbi.eu.
TABLE 5. International Initiative on Traumatic Brain Injury Research Studiesa
Project Title
Project Acronym and
Sample Size Funding Agency
Europe
Collaborative European NeuroTrauma Effectiveness Research in TBI CENTER-TBI (n = 5400) European Commission
Collaborative REsearch on ACute Traumatic brain Injury in IntensiVe care Medicine in
Europe
CREACTIVE (n = 7000) European Commission
United States
Transforming Research And Clinical Knowledge in Traumatic Brain Injury TRACK-TBI (n = 2700) NIH/NINDS
Approaches and Decisions for Acute Pediatric TBI ADAPT (n = 1000) NIH/NINDS
Managing severe TBI without ICP monitoring—guidelines development and testing (n = 780) NIH/NINDS
Canada
Predicting and preventing postconcussive problems in paediatrics (5P) study: protocol
for a prospective multicentre clinical prediction rule derivation study in children with
concussion.
5P (n = 2000) CIHR/ONF
Improving the diagnosis and treatment of mTBI in children and youth: the power of
common data
Common data (n = 1000) CIHR/FRQS
A longitudinal prospective study of mTBI in youth ice hockey players Safe to play (n = 1000) CIHR/HBI
Post-concussion Syndrome in youth: assessing the GABAergic effects of melatonin PLAYGAME (n = 166) CIHR
Neurocare: a clinical decision-making tool in youth mTBI NEUROCARE (n = 1400) CIHR/OBI
aCIHR, Canadian Institute of Health Research; FRQS, Fonds de recherche du Quebec—Sante; GABA, gamma-aminobutyric acid; HBI, Hotchkiss Brain Institute; ICP, intracranial
pressure; mTBI, mild TBI; NIDS, National Institute of Neurological Disorders and Stroke; NIH, National Institutes of Health; OBI, Ontario Brain Institute; ONF, Ontario Neurotrauma
Foundation; TBI, traumatic brain injury.
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Figure 2 presents a graphical representation of the components
and ambitions of the CENTER-TBI project, for which the
CENTER-TBI core data study and registry form the basis.
We expect the CENTER-TBI project to bring benefits to
patients, healthcare professionals, and policymakers.
Patients
TBI is not limited by any borders. The need for European action
is dictated by national and regional differences in resource,
treatment approaches, and healthcare delivery, which impact on
outcome. These inequalities in treatment provision and outcome
are not small: analysis of clinical trial data shows 3.8-fold
differences in risk adjusted outcomes across Europe,4 and a recent
EU report27 recognized that 100 000 lives could be saved
annually if injury mortality rates across Europe could be reduced
to the lowest observed national rate. CENTER-TBI will provide
robust guidelines on best clinical practice, ensuring that every EU
citizen obtains the best possible care, regardless of country or
region of residence. This will improve outcome and quality of life
for individual patients. We will also develop accessible informa-
tion for patients and families, empowering them as partners in
their own care. This will include information on early and reliable
outcome prediction (providing hope and decreasing unrealistic
expectations).
Various approaches will be adapted to enhance visibility and
interaction with patient groups; these include an open website,
press releases, establishment of a public information platform,
and use of social media. TBI is the commonest cause of deaths in
hospital trauma attendances; hence, we would anticipate our
CER findings to save 20 000 EU lives per annum in
a predominately economically active population, and reduce
disability in survivors.
Healthcare Professionals
We anticipate that our study will transform characterization of
TBI and improve detection and understanding of disease
processes, mirroring the recommendations of the National
Academy of Sciences on the importance of developing a new
taxonomy in the context of precision medicine. The expected
impact of CENTER-TBI is displayed in Figure 3, adapted from
the NAS report. We expect that improved disease character-
ization and identification of best practices will lead to therapies
that are better targeted and more individually oriented
(precision medicine). Knowledge gained from the CER analyses
will be integrated with systematic reviews of the existing
literature to produce improved and harmonized clinical guide-
lines, facilitating constant improvement by the clinical neuro-
trauma community.
FIGURE 2. Graphical presentation showing interdependencies of the components and work packages of the Collaborative
European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (TBI) project. MR, magnetic resonance; WP, work
package. This figure is presented in full color online.
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Policymakers
Insight into current epidemiological patterns of TBI across
member states will inform prevention campaigns, targeted to
needs at national levels. Our focus on the impact of systems of
care and organizational aspects of care delivery could yield
substantial benefits: for example, introduction of the UK
National Institute for Health and Care Excellence Guidelines
for TBI management was associated with a 12% reduction in
TBI mortality.28 More efficient and targeted care and improved
outcome will reduce costs. New performance indicators and
improved prognostic models will facilitate benchmarking and
assessments of quality of care.
In summary, the CENTER-TBI project will contribute
towards the overall goals of InTBIR, by identifying more
effective and efficient treatment provision, thus improving
outcome and reducing costs. The science in the project
will provide novel information on disease processes, treatment,
outcome, and prognosis in TBI, identifying new therapeutic
targets and therapies, while the CENTER-TBI repositories will
ensure opportunities for legacy research. Thus, the project has
the potential to improve current healthcare and its delivery at
both population and individual levels, deliver early scientific
advances that could improve the care of patients with TBI, and
provide a rich investment for future biomedical research.
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